https://mc06.manuscriptcentral.com/cjpp-pubs µg/paw and anti-inflammation: 10.6 mg/kg). Therefore, we concluded that the interactions between diclofenac and pyrilamine are synergistic. Our data suggest that the diclofenacpyrilamine combinations can interact at the systemic and local peripheral levels, thereby offering a therapeutic alternative for the clinical management of inflammatory pain.
Introduction
The treatment of painful and inflammatory conditions may include pharmacological and nonpharmacological therapies. Due to the role played by prostaglandins on these conditions, nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed as an initial or definitive therapy (Nalamachu 2013) . However, the clinical management of some moderately to severely painful and/or inflammatory conditions using NSAIDs alone could produce a limited therapeutic effect and fail to provide adequate pain relief for the patients (Nalamachu 2013; Ortiz 2010) . Therefore, several international guidelines recommend the use of NSAIDs along with an adjuvant analgesic drug to produce more effect pain relief. In this sense, the combination of NSAIDs with acetaminophen, antidepressants, anticonvulsants, local anesthetics, opioids, or antihistamines is recommendable in situations of moderate to severe pain (Moore et al. 2015; Ortiz 2010; Ortiz et al. 2009 ). In this particular case, the two main challenges over the past decades were to improve the analgesic efficacy and minimize the side effects. Thus, researchers continue to experiment with different combinations of analgesic drugs in animal models of pain and inflammation (Moore et al. 2015) . Later, clinical researchers analyzed these findings in order to investigate their possible clinical utility.
The contribution of histamine and its receptors in neurogenic inflammation and nociception has been widely demonstrated in preclinical models (Rosa and Fantozzi 2013) . In clinical conditions, some antihistamines have demonstrated analgesic effects when used as a monotherapy. Several clinical studies completed between the 1960s and 1980s found that significant analgesic effects were produced by the single administration of the histamine receptor blockers diphenhydramine, orphenadrine, pyrilamine, cimetidine, phenyltoloxamine, and hydroxyzine (Fujita et al. 2013; Raffa 2001; Rumore and Schlichting 1986 ). More recently, Fujita et al. (2013) found that the histamine H 1 -receptor antagonist diphenhydramine was able to produce analgesia as a simple entity. The authors proved that a 1% D r a f t diphenhydramine ointment produced a better analgesic activity than indomethacin when given to patients with osteoarthritis and/or osteoarthritis pain (Fujita et al. 2013) . However, the use of histamine H 1 -receptor antagonists alone for the relief of clinical pain is not authorized (Fujita et al. 2013) . Therefore, antihistaminic agents are commonly used in combination with analgesics, NSAIDs, caffeine, or decongestants in the management of pain and/or common cold symptoms (Kim et al. 2015; Ortiz 2010; Ortiz et al. 2009) . Recently, our group demonstrated that, in Mexican students, the most common medication prescribed by physicians and used in self-medication (SM) to treat dysmenorrheic pain was an over-the counter (OTC) medication containing a mixture of paracetamol (analgesic), pamabrom (xanthine with diuretic activity), and pyrilamine (histamine H 1 -receptor antagonist) (Ortiz 2010; Ortiz et al. 2009 ). In this case, it is possible to suggest that the pamabrom-induced pharmacological effects are involved in the analgesic activities produced by paracetamol and pyrilamine in the management of pain in women with primary dysmenorrhea. The antinociceptive and anti-inflammatory effects and the gastric damage potential resulting from the combination of pyrilamine with an NSAID such as diclofenac have never been studied. Therefore, we aimed to determine the type of drug interaction produced by a diclofenacpyrilamine combination on nociception, inflammation and gastric damage in rodents.
Materials and Methods

Animals
Female rats (Wistar strain; aged 7-9 weeks; weight range 180-220 g) were used in our study.
Five to eight animals were used per experimental group. Efforts were made to minimize animal suffering and to reduce the number of animals used. Each rat was used in only one experiment. The study was conducted according to the ethical guidelines previously reported D r a f t by Zimmermann (1983) , and all experiments were approved by an independent committee at our Institution (CINVESTAV, IPN, México, D.F. Mexico).
Drugs
Formaldehyde, diclofenac, and pyrilamine were obtained from Sigma (St. Louis, MO, USA). Diclofenac and pyrilamine were dissolved in 0.9% saline solution (vehicle).
Measurement of Antinociceptive Activity
The rat paw 1% formalin test was used to assess nociceptive and antinociceptive effects (Ortiz 2011) . Fifty microliters of 1% formalin were injected subcutaneously (s.c.) in the right hind paw, and the flinching behavior was quantified. The nociceptive behavior showed a biphasic pattern (Ortiz 2011) . The number of flinches yielded a biphasic curve, and the area under the curve was calculated for both phases.
Local peripheral Antinociception
Twenty minutes before the formalin injection, local peripheral injections with vehicles or different doses of diclofenac (10, 30, 100 and 300 µg/paw), pyrilamine (30, 100, 300 and 1000 µg/paw), or a diclofenac-pyrilamine combination (42.9, 85.8, 171.7 and 343.4 µg/paw) were performed. The tester was blinded to the administration of the different treatments.
Systemic Antinociception
Thirty minutes before injecting the 1% formaldehyde solution, vehicle or different doses of the tested formulations were administered orally, including diclofenac (10, 18, 30 and 56 mg/kg), pyrilamine (3, 10, 30 and 56 mg/kg), or a diclofenac-pyrilamine combination (4.4, 8.8, 17.7, and 35 .4 mg/kg). The tester was blinded to the administration of the different treatments. All treatments were administered in a volume of 4 ml/kg.
Measurement of carrageenan-induced paw inflammation
Inflammation and drug-induced anti-inflammatory effects were evaluated using the carrageenan-induced paw edema test (Bignotto et al. 2009; Ortiz et al. 2010a (4.7, 9.5, 18.9 and 37.9 mg/kg) were administered orally. Thirty minutes after drug administration, 100 microliters of a 1% carrageenan solution were administered subcutaneously (s.c.) into the paw. Finally, six hours after the carrageenan administration, the paw volumes were measured (Bignotto et al. 2009; Ortiz et al. 2010a ). The paw inflammation tester was blinded to the administration of the different treatments. All treatments were administered in a volume of 4 ml/kg.
Measurement of gastric damage
Independent groups of animals were given an oral (p.o.) dose of vehicle or treatment. The different treatments were diclofenac (10-56 mg/kg), pyrilamine (3-56 mg/kg) or a diclofenacpyrilamine combination (4.4-35.4 mg/kg). The drug doses employed in these experiments are the same doses used in the systemic antinociception experiments. The rats were euthanized three hours after drug administration.
Other groups of animals orally received vehicle or a different dosage of drug, including diclofenac (3-30 mg/kg), pyrilamine (3-56 mg/kg), or a diclofenac-pyrilamine combination (4.7-37.9 mg/kg). The drug doses employed in these experiments are the same doses used in the anti-inflammation experiments. The rats were euthanized six hours after drug administration. To evaluate the gastric damage produced by the drugs, the number of hemorrhagic lesions in the stomach of the tested rats was scored as previously reported (Ortiz et al. 2010a; 2010b) .
Motor coordination test
The capacity of the drugs to alter motor coordination was evaluated using the rotarod test.
Motor coordination was assessed before and at 1, 3 and 6 h after the administration of vehicle D r a f t 7 (1 ml), diclofenac (56 mg/kg), pyrilamine (56 mg/kg), or a combination of diclofenac (13.4 mg/kg) + pyrilamine (24.4 mg/kg), as published previously (Ortiz 2013; Ortiz et al. 2012 ).
Data Analysis Antinociception
The area under the curve (AUC) of the systemic and local peripheral antinociceptive effects produced by each individual and combined drug regimen was calculated as previously described (Ortiz 2013; Ortiz et al. 2012 ). The percentage of antinociception for the second phase of the assay was determined according to the following equation ( 
Anti-inflammation
Differential paw volume (DPV) data were determined using the following formula: DPV = paw volume at 6 h -basal paw volume. The percentage of anti-inflammation for each drug treatment was calculated according to the following equation (Ortiz et al. 2010a 
Drug combinations
The effective dose 30 (ED 30 ) for systemic antinociception and effective dose 40 (ED 40 ) for local peripheral antinociception and anti-inflammation were calculated as reported by Tallarida (2000) . The ED 30 and ED 40 are the dose that produced the 30% and 40% of the maximal observable effects, respectively. The interactions between diclofenac and pyrilamine were characterized by isobolographic exploration (Ortiz 2013; Ortiz et al. 2010a; 2010b; 2012; Wagner and Ulrich-Merzenich 2009) . Because the biological responses induced by diclofenac and pyrilamine were lower than 50%, we used the ED 30 for systemic antinociception and the ED 40 for local antinociception and anti-inflammation (Ortiz 2013; Ortiz et al. 2010a; 2010b) . Then, the concomitant administration of both drugs (diclofenac + pyrilamine) was determined based on the ED 30 (Ortiz 2013; Ortiz et al. 2010a; 2010b; Tallarida 2002) . To enhance the analysis of the results, an interaction index (γ) value was obtained using the following formula: γ = experimental ED 30 or ED 40 of combinations/ theoretical ED 30 or ED 40 of combinations. The γ value indicated the kind of pharmacological interaction as follows: γ = 1, additive interaction; γ > 1, antagonism; γ < 1, synergistic interaction (Ortiz 2013; Ortiz et al. 2010a; 2010b; Tallarida 2002 ).
Statistical Analyses
The dose-response curves were evaluated for significance using the one-way ANOVA and Dunnett´s test. The comparison between theoretical and experimental values was realized using the Student's t-test (Ortiz 2013; Ortiz et al. 2010a; 2010b; Tallarida 2000 
Results
Antinociceptive and anti-inflammatory activities produced by diclofenac and pyrilamine
The local peripheral administration of formalin produced a flinching behavior indicative of nociception. The local peripheral and systemic administration of diclofenac and pyrilamine D r a f t produced a dose-dependent antinociceptive effect during the second phase (p < 0.05; Figures   1 and 2 ). The ED 40 values for local diclofenac and pyrilamine administration were 207.1 ± 19.3 µg/paw and 479.7 ± 54.5 µg/paw, respectively. The ED 30 values for systemic diclofenac and pyrilamine administration were 22.0 ± 2.8 mg/kg and 48.8 ± 6.0 mg/kg, respectively.
The local peripheral administration of carrageenan produced a significant increase in the volume of the paws. The systemic administration of diclofenac and pyrilamine produced a dose-dependent anti-inflammatory effect (p < 0.05; Figure 3 ). The ED 40 values for the individual anti-inflammatory activity of systemically administered diclofenac or pyrilamine were 48.7 ± 5.9 mg/kg or 27.0 ± 3.2 mg/kg, respectively. At the end of the experiments, the animals were euthanized in a CO2 chamber. One hundred eighty rats were employed in these experiments. [anti-inflammation]) were significantly different from unity. These results suggest that at both the local and systemic levels, the interaction between diclofenac and pyrilamine is synergistic D r a f t in terms of antinociceptive and anti-inflammatory actions. At the end of the experiments, the animals were euthanized in a CO 2 chamber. Ninety rats were employed in these experiments.
Gastric injury
For both intervals (Figures 4 and 5) , the systemic administration of diclofenac, but not pyrilamine, caused hemorrhagic erosion of the stomach. The levels of gastric damage caused by the diclofenac and pyrilamine combinations (17.7-35.4 mg/kg and 37.9 mg/kg, at the third and sixth hour, respectively) were different from the damage measured in vehicle-treated animals (p < 0.05) (Figures 4 and 5) . One hundred eighty rats were employed in these experiments.
Figures 4 and 5 should be here.
Effect of diclofenac, pyrilamine, and diclofenac + pyrilamine in combination on motor coordination
Systemic treatment with diclofenac, pyrilamine or the mixture of these drugs did not alter the motor capacity in the experimental animals (Table 2) (p > 0.05). At the end of the experiments, the animals were euthanized in a CO 2 chamber. Twenty three rats were employed in these experiments. 
Discussion
Antinociceptive effect of diclofenac, pyrilamine and diclofenac-pyrilamine combinations
In a normal tissue, pain is elicited by stimuli that potentially or actually damage the tissue. However, this physiological nociceptive pain is an alarm sensation that is absolutely critical for survival. Indeed, physiological nociceptive pain has the capacity to initiate an immediate and adequate escape response. The application of a harmful or damaging stimulus to a tissue causes pain and an inflammatory response, which are equal in magnitude to the In previous studies, the synergistic interaction between diclofenac and analgesics, neuromodulators, or plant extracts have been widely demonstrated using preclinical models D r a f t (Acosta-Madrid et al. 2009; De Paz-Campos et al. 2014; Jiménez-Andrade et al. 2003; Picazo et al. 2006) . In addition, we demonstrated a synergistic relaxing effect of a pyrilamine and paracetamol combination in the uterine tissue . Other authors demonstrated that combining sub-effective doses of pyrilamine and CGRP 8-37, a calcitonin gene-related peptide type 1 (CGRP 1 ) receptor antagonist, produced a synergistic antinociceptive effect on formalin-induced behavior (Mobarakeh et al. 2011) . Our isobolographic analysis demonstrated a synergistic interaction between diclofenac and pyrilamine in both systemic and local peripheral antinociception. These effects can be due to the association or sum of the different mechanisms of action of both drugs. In other words, the diverse mechanisms induced by diclofenac (Gan 2010; Ortiz 2011; Ortiz et al. 2012; Voilley et al. 2004 ) are synergistically interacting with those of pyrilamine (Galeotti et al. 1999; 2002; Wang and Kotlikoff 2000) in the antinociceptive effect. Treatment with diclofenac, pyrilamine or the diclofenac + pyrilamine combinations did not alter motor coordination in the rats. Therefore, the antinociceptive effect induced by the drugs does not seem to result from a motor alteration.
Anti-inflammation produced by single drugs and their combination
The carrageenan-induced paw inflammation model is widely used to assess the antiinflammatory effects of drugs. The effect of carrageenan-induced edema is associated with a leukocyte response and the release of active substances, such as histamine, kinins, nitric oxide, serotonin, and prostaglandins (Marzocco et al. 2004; Nacife et al. 2004; Weissmann 1993 ). In the present study, an anti-inflammatory effect was observed with the systemic administration of diclofenac (Gan 2010). Likewise, pyrilamine administration elicited a significant anti-inflammatory effect at higher doses compared with those employed to block histamine-induced inflammation in the rat paws (Ezeamuzie and Umezurike 1989 Singh et al. 2000) . That is explained by the fact that those authors used doses ranging from 1 to 5 mg/kg. In our study, we found a significant antiinflammatory effect at doses ranging between 10 and 56 mg/kg. It is probable that the inhibition of the histamine receptors influences these effects. However, other mechanisms of action cannot be excluded. For example, the activation of the G i protein pathway and K + channels or the blockade of non-selective cation currents could be involved (Galeotti et al. 1999; 2002; Ortiz et al. 2011; Wang and Kotlikoff 2000) .
Our isobolographic analysis demonstrated a significantly synergistic interaction in the antiinflammatory effect induced by the diclofenac-pyrilamine mixture. Due to the participation of prostaglandins and histamine in the inflammatory reaction, it is very probable that the mixture is blocking the histamine receptors and prostaglandin production. However, the identification of the exact mechanism of action behind this synergism requires further investigation.
Gastric damage produced by single drugs and their combination
The introduction and acceptability of a new drug or combination of drugs are based on a satisfactory balance between the benefits and risks. Many experimental and clinical investigations demonstrated the benefits and gastrointestinal damage of NSAIDs. Several therapeutic strategies have been employed to increase the efficacy and decrease the gastrointestinal damage risk of NSAIDs (Lazzaroni and Porro 2009). Therefore, we evaluated the gastric damage produced by diclofenac and pyrilamine alone or in combination.
Diclofenac produced significant gastric injury at 3 and 6 hours. Additionally, insignificant gastric lesions were produced by pyrilamine alone in all animals at 3 and 6 hours. The highest dose of the diclofenac-pyrilamine combination produced serious gastric injury (17.7-35.4 mg/kg and 37.9 mg/kg, at the third and sixth hour, respectively). However, the gastric damage scores resulting from the highest doses of diclofenac + pyrilamine systemic administration at D r a f t three and six hours appeared lower than the scores resulting from the highest doses of diclofenac alone. The use of a lower diclofenac dose in the combination suggests that the present mixture could be a beneficial therapeutic option. However, the advantage of this combination at the gastric toxicity level in the clinic requires further investigation.
Experimental animal models are an important resource for studying human diseases.
Animals such as rodents and larger species have been largely employed to determine the physiopathology of various painful conditions and serve as experimental basis for mechanistic investigations and testing new therapeutic interventions. Although there are not animal models that mimic acute or chronic clinical pain conditions with complete fidelity, several animal models are used to evaluate the security and efficacy of NSAIDs and non-NSAIDs. In the present study, the efficacy and security of the diclofenac-pyrilamine combination were assessed on the rat formalin test. The diclofenac and pyrilamine oral dose used in the present study appear to be larger than those dose employed clinically (Derry et al. 2015; Ortiz 2010; Standing et al. 2011) . It is probable that the observed difference may be due to species 
